JeebeeTan
2021-07-30
👍🏻
Is a Meltdown on the Way for Moderna Stock?
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":806815754,"tweetId":"806815754","gmtCreate":1627648548678,"gmtModify":1633757469587,"author":{"id":3586427066022075,"idStr":"3586427066022075","authorId":3586427066022075,"authorIdStr":"3586427066022075","name":"JeebeeTan","avatar":"https://static.tigerbbs.com/da4f50945d55300b216529b90399ccea","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>👍🏻</p></body></html>","htmlText":"<html><head></head><body><p>👍🏻</p></body></html>","text":"👍🏻","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/806815754","repostId":2155373781,"repostType":4,"repost":{"id":"2155373781","kind":"highlight","pubTimestamp":1627647922,"share":"https://www.laohu8.com/m/news/2155373781?lang=&edition=full","pubTime":"2021-07-30 20:25","market":"us","language":"en","title":"Is a Meltdown on the Way for Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2155373781","media":"Motley Fool","summary":"There are certainly reasons to think the biotech stock is overpriced right now.","content":"<p>Move over, Murphy's law. Everything that could go right for <b>Moderna</b> (NASDAQ:MRNA) seems to be going right. The company was added to the <b>S&P 500</b> index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.</p>\n<p>However, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f6c071faeb9786d52d87adcab160eab7\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Lofty heights</h2>\n<p>There's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest biotech stocks on the market.</p>\n<p>Let's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for <b>Pfizer</b>. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.</p>\n<p>Consider <b>Regeneron</b> and <b>Vertex</b>, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex <i>combined</i>.</p>\n<h2>Considerable uncertainty</h2>\n<p>Moderna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.</p>\n<p>No one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.</p>\n<p>Perhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.</p>\n<p>Remember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.</p>\n<p>This lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.</p>\n<h2>A meltdown in the making?</h2>\n<p>A sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.</p>\n<p>I've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.</p>\n<p>Still, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.</p>\n<p>There's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.</p>\n<p>Even if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.</p>\n<p>The company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is a Meltdown on the Way for Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs a Meltdown on the Way for Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 20:25 GMT+8 <a href=https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155373781","content_text":"Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.\nHowever, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?\nImage source: Getty Images.\nLofty heights\nThere's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna one of the biggest biotech stocks on the market.\nLet's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for Pfizer. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.\nConsider Regeneron and Vertex, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex combined.\nConsiderable uncertainty\nModerna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.\nNo one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.\nPerhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.\nRemember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.\nThis lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.\nA meltdown in the making?\nA sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.\nI've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.\nStill, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.\nThere's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.\nEven if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.\nThe company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.","news_type":1},"isVote":1,"tweetType":1,"viewCount":252,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/806815754"}
精彩评论